Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases.
BACKGROUND
Cyclin E and p27 play pivotal roles in cancer development and progression. We investigated whether the prognosis in cases of non-small cell lung cancer without lymph node metastases that underwent complete resection could be associated with tissue expression of cyclin E, p27, and Ki-67.


METHODS
Tumors from 62 patients at least 5 years after surgery were assessed by immunohistochemistry for expression of cyclin E, p27, and Ki-67. Disease-free survival (DFS) after surgery was used to evaluate disease prognosis. We also investigated the relationship between expression of these factors and postoperative recurrence.


RESULTS
In non-small cell lung cancer, p27-negative expression and pT factor were significantly unfavorable prognostic factors in multivariate analysis. The DFS rate in cyclin E-positive expression was significantly lower than in cyclin E-negative expression. Similarly, p27-negative expression and high Ki-67 expression correlated with a shortened DFS rate. In combinations of expression of cyclin E and p27, the cyclin E-negative/p27-positive group had a significantly higher DFS rate than did the other groups. According to histological type, there were correlations between the risk of postoperative recurrence and expression of these three biological factors, especially in adenocarcinoma.


CONCLUSIONS
By analyzing the expression of cyclin E, p27, and Ki-67 of tumor cells, it was possible to extract the patient group for whom closer follow-up and postoperative treatment is necessary to improve survival rate.
Takahashi
Seiji
S
First Department of Surgery, Hirosaki University School of Medicine, 5 Zaihu-cho, Hirosaki, Aomori 036-8562, Japan. seiji@hospital.hachinohe.aomori.jp
Kamata
Yoshimasa
Y
Tamo
Wakako
W
Koyanagi
Masashi
M
Hatanaka
Ryou
R
Yamada
Yoshitsugu
Y
Tsushima
Takao
T
Takaya
Shunichi
S
Fukuda
Ikuo
I
D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000473:pathology / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000473:pathology / Q000601:surgery*; D019927:Cyclin E / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis*; D008175:Lung Neoplasms / Q000737:chemistry / Q000473:pathology / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D012008:Recurrence
D014408:Biomarkers, Tumor; D019927:Cyclin E; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; C413374:p27 antigen